A breakthrough vest with technology to personalize lutetium-177 DOTATATE among people with metastatic, somatostatin-receptor-2-positive neuroendocrine tumors developed by University of Washington researchers yielded similar or more precise organ-specific washout rates over seven days to 21 days, compared with three to four quantitative SPECT/CT images collected over a week, which is the current gold standard. The wearable technology was highlighted at the SNMMI Annual Meeting.
Study evaluates novel vest personalizing Lu-177 DOTATATE for NETs
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.